Corporate Finance

Vator Securities focuses on identifying and financing growth companies as they expand and develop into tomorrow’s market leaders.

Equity Research

Commissioned research by Vator Securities is offered to selected life science companies – "By Invitation Only". Commissioned researches are published continuously.

Vator Securities Unicorn Summit was held on November 27th 2019 at IVA Conferens Center in Stockholm and was attended by over 200 guests.

Click here to watch the presentations

Vator Securities advises SenzaGen on 106 MSEK Directed and Rights Issue

12 November 2019

The subscribers in the Directed Share Issue are, amongst other, AP-4 (The Fourth Swedish National Pension Fund), Ålandsbanken Abp, Consensus Asset Management, Kavaljer, Segersta and Thomas Olausson.

AlzeCure Pharma – A win for the amyloid hypothesis is a win for AlzeCure

24 October 2019

Biogen’s progress with its Alzheimer’s disease drug (aducanumab) gives support for the amyloid hypothesis and significantly strengthens AlzeCure’s case.

The company’s Alzstatin-program focuses on disease-modifying therapies for early Alzheimer’s disease by reducing the production of amyloid beta.

Vator Securities Sole Bookrunner in Nanoform SEK 106 million private placement

4 July 2019

Nanoform, an innovative medicine enabling nanotechnology company, announced the completion of a private placement totaling €10 million, with Ilmarinen Mutual Pension Insurance Company and Mandatum Life Insurance Company (Sampo Group) acting as anchor investors.

Vator Securities advises Empros Pharma on 40 MSEK private placement

4 July 2019

Subscribers in the issue are both existing shareholders Thomas Eldered, Directors of the Board and Management as well as new shareholders with extensive investment experience from the Life Science sector. Thomas Eldered remains the main shareholder in the Company.

More News